Open Access
Med Sci (Paris)
Volume 37, Number 11, Novembre 2021
Page(s) 968 - 970
Section Le Magazine
Published online 01 December 2021
  1. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020; 26 : 845–8. [CrossRef] [PubMed] [Google Scholar]
  2. Mazanec MB, Kaetzel CS, Lamm ME, et al. Intracellular neutralization of Sendai and influenza viruses by IgA monoclonal antibodies. Adv Exp Med Biol 1995; 371A : 651–4. [CrossRef] [Google Scholar]
  3. Asahi-Ozaki Y, Yoshikawa T, Iwakura Y, et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol 2004 ; 74 : 328–335. [CrossRef] [PubMed] [Google Scholar]
  4. Sterlin D, Gorochov G. When therapeutic IgA antibodies might come of age. Pharmacology 2021; 106 : 9–19. [CrossRef] [PubMed] [Google Scholar]
  5. Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med 2021; 13 : eabd2223. [CrossRef] [PubMed] [Google Scholar]
  6. Xiong N, Fu Y, Hu S, et al. CCR10 and its ligands in regulation of epithelial immunity and diseases. Protein Cell 2012 ; 3 : 571–580. [CrossRef] [PubMed] [Google Scholar]
  7. Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature 2020; 584 : 120–4. [CrossRef] [PubMed] [Google Scholar]
  8. Wang Z, Lorenzi JCC, Muecksch F, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med 2021; 13 : eabf1555. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.